ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

APTO Aptose Biosciences Inc

1.61
0.11 (7.33%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 137,093
Bid Price 1.62
Ask Price 1.67
News -
Day High 1.70

Low
1.36

52 Week Range

High
10.125

Day Low 1.50
Share Name Share Symbol Market Stock Type
Aptose Biosciences Inc APTO NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.11 7.33% 1.61 18:34:00
Open Price Low Price High Price Close Price Previous Close
1.50 1.50 1.70 1.66 1.50
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
683 137,093 US$ 1.61 US$ 221,312 - 1.36 - 10.125
Last Trade Type Quantity Price Currency
18:16:16 formt 146 US$ 1.61 USD

Aptose Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
502.35M 7.54M - 0 -41.82M -5.54 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Aptose Biosciences News

Date Time Source News Article
3/01/202416:00Edgar (US Regulatory)Form 8-K - Current report
2/14/202415:51Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial..
2/07/202417:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/07/202416:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/07/202416:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/07/202416:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/07/202415:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/07/202415:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/07/202415:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/07/202415:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/07/202415:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/07/202415:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No APTO Message Board. Create One! See More Posts on APTO Message Board See More Message Board Posts

Historical APTO Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.511.701.461.5463,6370.106.62%
1 Month1.901.901.361.6175,054-0.29-15.26%
3 Months2.392.601.361.9092,112-0.78-32.64%
6 Months2.913.321.362.1671,246-1.30-44.67%
1 Year9.70210.1251.365.0698,717-8.09-83.41%
3 Years89.1096.901.3635.07474,983-87.49-98.19%
5 Years30.75138.78751.3664.37779,662-29.14-94.76%

Aptose Biosciences Description

Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Luxeptinib, its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL). HM43239 is an oral potent myeloid kinome inhibitor, targeting a constellation of kinases operative in myeloid malignancies.

Your Recent History

Delayed Upgrade Clock